Skip to main content

Table 2 Adverse events

From: A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

Patients 1 mg/kg/day 2 mg/kg/day Alternating All n = 24
Cohort 1/Schedule A n = 10 Cohort 2 n = 8 Schedule B n = 6
Completed 1st cycle 7/10 (70 %) 5/8 (63 %) 5/6 (83 %) 17/24 (71 %)
Toxicities grade (%) 2 3 4   2 3 4   2 3 4  
Rash 1     4 2       29.2
Diarrhea 3 1    1        20.8
Anorexia 5 2    4     4    62.5
Weight loss 1 1        2    16.7
Anxiety 1            4.2
Nausia 3     1        16.7
Vomiting 4            16.7
Fatigue 4 4    5 1    2 2   75.0
Muscle weakness 1 1    6     1 1   41.7
Myalgia   2    3 1    1    29.2
Rhabdomyolysis        1      4.2a
  1. aStudy related death